Plantation; Research Site:
AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients.

Pompano Beach; Research Site:
QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

Port St Lucie; Research Site:
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

Port St Lucie; Research Site:
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection

Port St Lucie; Research Site:
QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

Port St Lucie; Research Site:
AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients.

Sarasota ; Research Site:
A Study to Assess Fuzeon (Enfuvirtide) in Human Immunodeficiency Virus (HIV)-infected Subjects With Renal Impairment

Sarasota ; Research Site:
A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

Sarasota ; Research Site:
QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

South Miami; Research Site:
QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

South Miami; Research Site:
WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.

South Miami; Research Site:
AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients.

Tallahassee; Research Site:
QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

Tamarac; Research Site:
QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

Tampa; Research Site:
QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

Vero Beach; Research Site:
QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

Vero Beach; Research Site:
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection

West Palm Beach; Palm Beach Research Center
HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox?

Georgia

Atlanta; Atlanta ID Group
HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox?

Atlanta; Research Site:
AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients.

Atlanta; Research Site:
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection

Atlanta; Research Site:
QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

Atlanta; Research Site:
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection

Atlanta; Research Site:
A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

Atlanta; Research Site:
WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.

Decatur; Research Site:
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection

Decatur; Research Site:
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

Decatur; Research Site:
QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

Lawrenceville; Research Site:
QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

Macon ; Research Site:
AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients.

Macon ; Research Site:
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

Macon ; Research Site:
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection

Idaho

Boise; Research Site:
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection

Boise; Research Site:
QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

Illinois

Chicago; The CORE Center
HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox?

Chicago; Northstar Medical Center
HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox?

Chicago; Research Site:
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.

Chicago; Research Site:
AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients.

Chicago; Research Site:
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection

Chicago; Research Site:
QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

Chicago; Research Site:
WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.

Chicago; Research Site:
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection

Springfield; Research Site:
QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

Indiana

Indianapolis; Indiana University School of Medicine
HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox?

Iowa

Iowa City; University of Iowa

Click here to sign up to receive emails about new trial listings. Clinical Trials: HIV Infections Alabama Birmingham; University of Alabama at Birmingham HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Birmingham; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Hobson City ; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Hobson City ; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Hobson City ; Research Site: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients Arizona Phoenix; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Phoenix; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Phoenix; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Phoenix; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Tucson ; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Arkansas Little Rock; Health for Life Clinic, PLLC HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? California Bakersfield; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Bakersfield; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Berkeley; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Berkeley; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Beverly Hills; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Burbank; Providence Clinical Research HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Fountain Valley; CSI Clinical Trials, Inc. HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Fountain Valley; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Fountain Valley; Research Site: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients Hayward; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Long Beach; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Los Angeles; Peter J. Ruane, MD, Inc. KD-247: A New Investigational Anti-HIV Drug Los Angeles; AltaMed Health Services Corporation HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Los Angeles; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Los Angeles; Research Site: WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV. Los Angeles; Research Site: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients Los Angeles; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Los Angeles; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Los Angeles; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Los Angeles; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Modesto; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Modesto; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Oakland; Alta Bates Summit Medical Center HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Oakland; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Palm Springs; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Palm Springs; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Rancho Mirage; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection San Francisco; Benchmark Clinical Research HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? San Francisco; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. San Francisco; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection San Mateo; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Santa Clara; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Stanford; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Stanford; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Tarzana; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Tarzana; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Torrance ; Research Site: A Study to Assess Fuzeon (Enfuvirtide) in Human Immunodeficiency Virus (HIV)-infected Subjects With Renal Impairment Colorado Denver; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Denver; Research Site: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients Connecticut Norwalk; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Florida Bay Pines; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Boynton Beach; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Brandon; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Clearwater; Clinical Research of West Florida HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Daytona Beach; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Fort Lauderdale; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Fort Lauderdale; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Fort Lauderdale; Research Site: A Study to Assess Fuzeon (Enfuvirtide) in Human Immunodeficiency Virus (HIV)-infected Subjects With Renal Impairment Fort Lauderdale; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Fort Lauderdale; Research Site: WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV. Fort Lauderdale; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Fort Myers; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Fort Myers; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Ft. Lauderdale; Aaron Diamond AIDS Research Center KD-247: A New Investigational Anti-HIV Drug Ft. Lauderdale; Northpoint Medical, PA HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Jacksonville; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Jacksonville; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Miami; The Kinder Medical Group HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Miami; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Miami; Research Site: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients Miami; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Miami; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Miami Beach; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Miami Beach; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection North Miami Beach ; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection North Palm Beach; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection North Palm Beach; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Oakland Park; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Orlando; Orlando Immunology Center KD-247: A New Investigational Anti-HIV Drug Orlando; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Orlando; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Orlando; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Orlando; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Orlando; Research Site: A Study to Assess Fuzeon (Enfuvirtide) in Human Immunodeficiency Virus (HIV)-infected Subjects With Renal Impairment Orlando; Research Site: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients Orlando; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Pensacola; Infectious Diseases of NW Florida HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Plantation; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Plantation; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Kansas Topeka; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Wichita; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Kentucky Louisville; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Louisiana New Orleans; Research Site: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients Maryland Baltimore; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Baltimore; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Silver Spring; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Silver Spring; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Silver Spring; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Massachusetts Boston; Research Site: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients Boston; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Boston; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Michigan Berkley; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Detroit; Research Site: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients Ypsilanti; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Ypsilanti; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Minnesota Minneapolis; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Missouri Kansas City; Nemechek Health Renewal HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Kansas City; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Kansas City; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection St Louis; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. St Louis; Research Site: A Study to Assess Fuzeon (Enfuvirtide) in Human Immunodeficiency Virus (HIV)-infected Subjects With Renal Impairment St Louis; Research Site: WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV. St Louis; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection St Louis; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection St Louis; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. St Louis; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection St. Louis; St. Louis University Center for Vaccine Dev. HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? St. Louis; Washington University HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Montana Butte; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Nebraska Omaha; University of Nebraska Medical Center HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Nevada Las Vegas; Nevada AIDS Research and Education Society HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Las Vegas; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection New Jersey East Orange; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Englewood; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Jersey City; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Newark; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Newark; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Newark; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Newark; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Perth Amboy; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Somers Point; Research Site: A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection. Somers Point; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Somers Point; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Somers Point; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Somers Point; Research Site: A Study to Assess Fuzeon (Enfuvirtide) in Human Immunodeficiency Virus (HIV)-infected Subjects With Renal Impairment Union ; Research Site: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients Voorhees; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection West Orange; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection New York Albany; Albany Medical College KD-247: A New Investigational Anti-HIV Drug Albany; Research Site: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients Albany; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Briarcliff Manor; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Bronx; Biomedical Research Alliance of New York HIV Infection- 9 months Bronx; Biomedical Research Alliance of New York HIV - Children and Adolescents Bronx; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Manhasset; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Mt Vernon; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection New York; Mount Sinai Medical Center A multi-center, randomized, open-label, phase IIIb study investigating the safety and efficacy of Peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C infection in HIV infected persons who have failed to achieve a sustained virologic response following previous interferon therapy. New York; Mount Sinai Medical Center PEG-Interferon alfa-2b plus Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated with Interferon. New York; Aaron Diamond AIDS Research Center KD-247: A New Investigational Anti-HIV Drug New York; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. New York; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection New York; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. New York; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection New York; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Rochester; University of Rochester School of Medicine HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Rochester; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Rochester; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Rochester; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Staten Island; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Stony Brook; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection North Carolina Cary ; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Huntersville; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Huntersville; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Winston-Salem; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Winston-Salem; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Winston-Salem; Research Site: WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV. Ohio Akron; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Cincinnati; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Cleveland; Research Site: A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience Oklahoma Oklahoma City; Clinical Trials Unit HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Oregon Portland; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Portland; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Portland; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Pennsylvania Allentown; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Allentown; Research Site: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients Harrisburg; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Philadelphia; University of Pennsylvania HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Philadelphia; Research Site: A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection. Philadelphia; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Philadelphia; Research Site: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients Philadelphia; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Philadelphia; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Philadelphia; Research Site: A Study to Assess Fuzeon (Enfuvirtide) in Human Immunodeficiency Virus (HIV)-infected Subjects With Renal Impairment Philadelphia; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Philadelphia; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Pittsburg; Clinical Trials Research Services HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Reading; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Reading; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection West Reading; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Rhode Island Providence; Brown Medical School HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? South Carolina Charleston; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Columbia; University of South Carolina Division of Infectious Diseases HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Columbia; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Tennessee Nashville; Vanderbilt University HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Texas Austin; Research Site: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients Austin; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Austin; Research Site: A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience Dallas; Nicholaos C. Bellos, MD PA HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Dallas; Research Site: A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection. Dallas; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Dallas; Research Site: A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience Dallas; Research Site: WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV. Dallas; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Dallas; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Dallas; Research Site: A Study to Assess Fuzeon (Enfuvirtide) in Human Immunodeficiency Virus (HIV)-infected Subjects With Renal Impairment Fort Worth; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Fort Worth; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Fort Worth; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Fort Worth; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Galveston; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Galveston; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Harlingen; Valley AIDS Council HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Houston; Diversified Medical Practices HIV positive? Interested in an investigational vaccine for immune suppressed people, like those with HIV, to potentially protect against smallpox? Houston; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Houston; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Houston; Research Site: WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV. Houston; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Houston; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Houston; Research Site: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients Houston; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. San Antonio; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Virginia Annandale; Research Site: WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV. Annandale; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Annandale; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Fairfax ; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Hampton; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Hampton; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Hampton; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Washington Seattle; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Spokane ; Research Site: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Washington, DC Washington; Research Site: AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Washington; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Washington; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Washington; Research Site: QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection International Buenos Aires , Argentina; Research Site: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children. Santa Fe, Argentina; Research Site: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children. Adelaide, Australia; Research Site: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon. Brisbane, Australia; Research Site: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon. Brisbane, Australia; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Carlton, Australia; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Carlton, Australia; Research Site: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon. Liverpool, Australia; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Melbourne, Australia; Research Site: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon. Melbourne, Australia; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. South Yarra, Australia; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. South Yarra, Australia; Research Site: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon. Sydney, Australia; Research Site: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Sydney, Australia; Research Site: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon. Westmead, Australia; Research Site: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon. Bruxelles, Belgium; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Zaventem, Belgium; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Belo Horizonte, Brazil; Research Site: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children. Campinas, Brazil; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Campinas, Brazil; Research Site: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon Nova Iguaçu, Brazil; Research Site: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children. Porto Alegre, Brazil; Research Site: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children. Porto Alegre, Brazil; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Porto Alegre, Brazil; Research Site: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon Ribeirão Preto, Brazil; Research Site: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children. Rio De Janeiro, Brazil; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Rio De Janeiro, Brazil; Research Site: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon Salvador, Brazil; Research Site: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children. Salvador, Brazil; Research Site: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon Salvador, Brazil; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Sao Paulo, Brazil; Research Site: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children. Sao Paulo, Brazil; Research Site: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon Sao Paulo, Brazil; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Sofia, Bulgaria; Research Site: A Study of Fuzeon (Enfuvirtide) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection Calgary, AB, Canada; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Calgary, AB, Canada; Research Site: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon Edmonton, AB, Canada; Research Site: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon Edmonton, AB, Canada; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Halifax, NS, Canada; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Hamilton, ON, Canada; Research Site: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon Hamilton, ON, Canada; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Montreal, QC, Canada; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Montreal, QC, Canada; Research Site: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients Montreal, QC, Canada; Research Site: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon Montreal, QC, Canada; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Montreal, QC, Canada; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Ottawa, ON, Canada; Research Site: A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection. Ottawa, ON, Canada; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Ottawa, ON, Canada; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Ottawa, ON, Canada; Research Site: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon Saskatoon, SK, Canada; Research Site: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon Saskatoon, SK, Canada; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Toronto, ON, Canada; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Toronto, ON, Canada; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Toronto, ON, Canada; Research Site: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon Toronto, ON, Canada; Research Site: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients Toronto, ON, Canada; Research Site: A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection. Vancouver, BC, Canada; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Vancouver, BC, Canada; Research Site: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon Århus, Denmark; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Hvidovre, Denmark; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen København, Denmark; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Odense, Denmark; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Argenteuil, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Aulnay Sous Bois, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Avignon, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Basse-Terre, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Basse-Terre, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Besancon, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Bobigny, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Bordeaux, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Bordeaux, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Bordeaux, France; Research Site: A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection Boulogne, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Boulogne, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Caen, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Caen, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Colmar, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Colmar, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Creteil, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Fort-De-France, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Fort-De-France, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Garches, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Garches, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) La Roche Sur Yon, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Lagny-Sur-Marne, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Le Kremlin Bicêtre, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Levallois Perret, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Levallois Perret, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Lyon, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Lyon, France; Research Site: A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection Lyon, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Lyon, France; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Marseille, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Marseille, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Marseille, France; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Montpellier, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Montpellier, France; Research Site: A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection Nantes, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Nantes, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Nantes, France; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Nice, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Nice, France; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Nice, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Nimes, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Nimes, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Paris, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Paris, France; Research Site: A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection Paris, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Paris, France; Research Site: A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience Paris, France; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Paris, France; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Perpignan, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Pessac, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Pointe À Pitre, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Poitiers, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Poitiers, France; Research Site: A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience Pontoise, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Pontoise, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Rennes, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Rouen, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Saint Pierre, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Saint Pierre, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Saint-Denis, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Saint-Denis, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Saint-Dizier, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Strasbourg, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Strasbourg, France; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Suresnes, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Toulon, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Toulouse, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Toulouse, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Tourcoing, France; Research Site: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Tourcoing, France; Research Site: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Villejuif, France; Research Site: INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Aachen, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Berlin, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Berlin, Germany; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Berlin, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience Berlin, Germany; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Berlin, Germany; Research Site: A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection Bochum, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Bonn, Germany; Research Site: A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection Bremen, Germany; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Düsseldorf, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Essen, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Essen, Germany; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Frankfurt Am Main, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Frankfurt Am Main, Germany; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Frankfurt Am Main, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience Freiburg, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Giessen, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Grenzach-Wyhlen, Germany; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Hamburg, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Hamburg, Germany; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Hannover, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Hannover, Germany; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Heidelberg, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Koblenz, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Köln, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Köln, Germany; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Leipzig, Germany; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Mainz, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon München, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon München, Germany; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen München, Germany; Research Site: A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection Nürnberg, Germany; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Osnabrück, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Osnabrück, Germany; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Stuttgart, Germany; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Alessandria, Italy; Research Site: A Study of the Effect of Fuzeon (Enfuvirtide)-Based Therapy on Viral Load in HIV-Positive, Treatment-Naive Patients Arezzo, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Asti, Italy; Research Site: A Study of the Effect of Fuzeon (Enfuvirtide)-Based Therapy on Viral Load in HIV-Positive, Treatment-Naive Patients Bagno A Ripoli, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Benevento, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Bologna, Italy; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Brescia, Italy; Research Site: A Study of the Effect of Fuzeon (Enfuvirtide)-Based Therapy on Viral Load in HIV-Positive, Treatment-Naive Patients Brescia, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Caserta, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Catania, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Foggia, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Foggia, Italy; Research Site: A Study of the Effect of Fuzeon (Enfuvirtide)-Based Therapy on Viral Load in HIV-Positive, Treatment-Naive Patients Genova, Italy; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Genova, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Grosseto, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Lecco, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Lucca, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Milano, Italy; Research Site: A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection Milano, Italy; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Milano, Italy; Research Site: A Study of the Effect of Fuzeon (Enfuvirtide)-Based Therapy on Viral Load in HIV-Positive, Treatment-Naive Patients Milano, Italy; Research Site: A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience Milano, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Monza, Italy; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Napoli, Italy; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Napoli, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Padova, Italy; Research Site: A Study of the Effect of Fuzeon (Enfuvirtide)-Based Therapy on Viral Load in HIV-Positive, Treatment-Naive Patients Palermo, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Palermo, Italy; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Pavia, Italy; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Piacenza, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Reggio Emilia, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Roma, Italy; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Roma, Italy; Research Site: A Study of the Effect of Fuzeon (Enfuvirtide)-Based Therapy on Viral Load in HIV-Positive, Treatment-Naive Patients Roma, Italy; Research Site: A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience Roma, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Sassari, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Siena, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Taranto, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Torino, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Torino, Italy; Research Site: A Study of the Effect of Fuzeon (Enfuvirtide)-Based Therapy on Viral Load in HIV-Positive, Treatment-Naive Patients Udine, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Verbania, Italy; Research Site: ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Mexico City, Mexico; Research Site: A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience Mexico City, Mexico; Research Site: A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection Mexico City, Mexico; Research Site: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon Mexico City, Mexico; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Monterrey, Mexico; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Veracruz, Mexico; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Rotterdam, Netherlands; Research Site: A Study of the Safety of Viracept (Nelfinavir) in an Expanded Access Program in HIV-1 Positive Women Who are Pregnant or Who Want to Become Pregnant. Woerden, Netherlands; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Woerden, Netherlands; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Christchurch, New Zealand; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Chorzow, Poland; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Lodz, Poland; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Warszawa, Poland; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Warszawa, Poland; Research Site: A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection Wroclaw, Poland; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Amadora, Portugal; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Bucharest, Romania; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Constanta, Romania; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Kazan, Russian Federation; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Moscow, Russian Federation; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen St Petersburg, Russian Federation; Research Site: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Alicante, Spain; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Alicante, Spain; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Barcelona, Spain; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Barcelona, Spain; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Barcelona, Spain; Research Site: A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience Bilbao, Spain; Research Site: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Bilbao, Spain; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Cádiz, Spain; Research Site: A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience Castellon, Spain; Research Site: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Córdoba, Spain; Research Site: A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Tr